HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nadia Harbeck Selected Research

Tissue Extracts

11/2010Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
3/2007Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
3/2007European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers.
1/2006Procedures for the quantitative protein determination of urokinase and its inhibitor, PAI-1, in human breast cancer tissue extracts by ELISA.
3/2004Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
7/2003Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer.
6/2003Human kallikrein 8, a novel biomarker for ovarian carcinoma.
3/2003Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
8/2002Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
2/2002Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nadia Harbeck Research Topics

Disease

291Breast Neoplasms (Breast Cancer)
12/2022 - 01/2002
159Neoplasms (Cancer)
12/2022 - 01/2002
29Neoplasm Metastasis (Metastasis)
01/2022 - 01/2002
15Triple Negative Breast Neoplasms
11/2022 - 11/2015
15Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 06/2003
15Neutropenia
02/2021 - 06/2009
14Disease Progression
01/2022 - 06/2004
13Pathologic Complete Response
03/2022 - 06/2009
9COVID-19
11/2022 - 01/2020
9Carcinoma (Carcinomatosis)
04/2021 - 02/2002
9Febrile Neutropenia
02/2021 - 04/2006
8Fatigue
01/2021 - 05/2014
6Anemia
12/2020 - 03/2009
6Leukopenia
12/2020 - 01/2010
5Nausea
01/2021 - 07/2009
5Pain (Aches)
01/2020 - 01/2018
4Brain Neoplasms (Brain Tumor)
02/2022 - 01/2007
4Cardiotoxicity
09/2021 - 05/2005
4Infections
02/2021 - 06/2009
4Circulating Neoplastic Cells
01/2019 - 12/2015
4Thrombocytopenia (Thrombopenia)
09/2017 - 06/2009
3Noninfiltrating Intraductal Carcinoma (DCIS)
12/2021 - 02/2018

Drug/Important Bio-Agent (IBA)

76Hormones (Hormone)IBA
12/2022 - 01/2002
45Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2002
35Trastuzumab (Herceptin)FDA Link
10/2022 - 01/2003
28human ERBB2 proteinIBA
10/2022 - 12/2009
24AnthracyclinesIBA
10/2022 - 04/2006
23ErbB Receptors (EGF Receptor)IBA
10/2022 - 03/2010
21Proteins (Proteins, Gene)FDA Link
11/2021 - 01/2002
20Plasminogen Activator Inhibitor 1IBA
07/2019 - 01/2002
20Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2016 - 01/2002
17Epirubicin (Ellence)FDA LinkGeneric
10/2022 - 03/2007
17Estrogen ReceptorsIBA
03/2022 - 07/2004
17Docetaxel (Taxotere)FDA Link
12/2020 - 01/2006
16palbociclibIBA
01/2022 - 07/2015
15Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022 - 11/2009
13Biological ProductsIBA
01/2020 - 08/2002
12TamoxifenFDA LinkGeneric
12/2022 - 07/2004
12Paclitaxel (Taxol)FDA LinkGeneric
10/2022 - 03/2007
12Fulvestrant (Faslodex)FDA Link
01/2022 - 01/2011
11SteroidsIBA
01/2020 - 01/2002
11Letrozole (Femara)FDA LinkGeneric
01/2020 - 01/2007
11Tissue ExtractsIBA
11/2010 - 01/2002
10taxaneIBA
10/2022 - 01/2008
10Progesterone Receptors (Progesterone Receptor)IBA
01/2022 - 02/2005
9Aromatase InhibitorsIBA
12/2022 - 12/2007
9Ado-Trastuzumab EmtansineIBA
10/2022 - 01/2014
9Carboplatin (JM8)FDA LinkGeneric
10/2022 - 12/2011
9Messenger RNA (mRNA)IBA
07/2020 - 07/2003
8Lapatinib (GW572016)FDA Link
10/2021 - 01/2008
8Plasminogen InactivatorsIBA
07/2011 - 01/2002
7pertuzumabIBA
10/2022 - 03/2013
7Cyclin-Dependent Kinase 4IBA
01/2022 - 01/2017
7AntigensIBA
01/2022 - 08/2002
7Pharmaceutical PreparationsIBA
01/2022 - 01/2006
7Capecitabine (Xeloda)FDA Link
10/2021 - 08/2005
7GemcitabineFDA Link
04/2021 - 11/2015
7Fluorouracil (Carac)FDA LinkGeneric
12/2020 - 08/2005
7ParaffinIBA
07/2020 - 11/2008
7EnzymesIBA
09/2017 - 02/2002
7Indicators and Reagents (Reagents)IBA
11/2009 - 06/2003
6Taxoids (Taxanes)IBA
10/2022 - 04/2006
6ribociclibIBA
03/2022 - 01/2018
6Phenobarbital (Luminal)FDA Link
12/2021 - 12/2013
6RNA (Ribonucleic Acid)IBA
11/2021 - 04/2006
6Biological FactorsIBA
10/2021 - 01/2002
6130-nm albumin-bound paclitaxelIBA
10/2020 - 12/2015
6Biosimilar PharmaceuticalsIBA
09/2020 - 01/2016
6Formaldehyde (Formol)FDA Link
07/2020 - 11/2008
6Tumor Biomarkers (Tumor Markers)IBA
07/2011 - 11/2004
6Kallikreins (Kallikrein)IBA
03/2006 - 06/2003
5Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 05/2005
5pegfilgrastim (Neulasta)FDA Link
02/2021 - 01/2016
5DNA (Deoxyribonucleic Acid)IBA
12/2017 - 04/2006
5Serine Proteases (Serine Protease)IBA
10/2010 - 01/2006
5ImmunosorbentsIBA
01/2006 - 02/2002
4Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2020 - 04/2006
4LigandsIBA
10/2020 - 02/2005
4Anastrozole (Arimidex)FDA LinkGeneric
06/2020 - 12/2007
4Transcription Factors (Transcription Factor)IBA
01/2018 - 07/2007
4AfatinibIBA
03/2016 - 08/2012
4Plasminogen Activators (Plasminogen Activator)IBA
01/2016 - 08/2002
4Monoclonal AntibodiesIBA
10/2013 - 05/2005
4Estrogens (Estrogen)FDA Link
05/2012 - 11/2003
3pembrolizumabIBA
10/2022 - 01/2020
3Cadherins (E-Cadherin)IBA
01/2022 - 10/2018
3N-acetyltalosaminuronic acid (NAT)IBA
10/2021 - 01/2021
3Epidermal Growth Factor (EGF)IBA
10/2021 - 12/2008
3liposomal doxorubicin (Doxil)FDA Link
09/2021 - 01/2006

Therapy/Procedure

168Therapeutics
12/2022 - 02/2002
95Drug Therapy (Chemotherapy)
11/2022 - 01/2002
33Neoadjuvant Therapy
11/2022 - 01/2009
27Adjuvant Chemotherapy
01/2022 - 08/2002
14Radiotherapy
10/2021 - 01/2007
9Segmental Mastectomy (Lumpectomy)
01/2019 - 05/2006
6Mastectomy (Mammectomy)
12/2021 - 03/2008
5Precision Medicine
06/2020 - 09/2008
5Aftercare (After-Treatment)
11/2018 - 03/2008
4Drug Tapering
12/2019 - 01/2006
3Palliative Care (Palliative Therapy)
02/2022 - 01/2011